Our novel anti-biofilm strategy aims to address the burden of biofilm-mediated inflammation and progressive lung function. Read more on how we're working to combat chronic respiratory conditions.Our Science Meet our team: a strategically focused group of experts with deep therapeutic and vaccine development expertise.Meet The Team In the News Clarametyx Biosciences Announces Completion of Enrollment in Phase 2a Study of CMTX-101 in Cystic FibrosisOctober 16, 2025 Clarametyx Biosciences Announces FDA Grant Of Fast Track And Qualified Infectious Disease Product Designations For CMTX-101August 4, 2025 Clarametyx Biosciences Announces Positive Interim Analysis in Phase 2a Study Evaluating CMTX-101 for Infections Associated with Cystic FibrosisJune 16, 2025 CincyTech Invests in Clarametyx to Advance Breakthrough Anti-Biofilm Therapies for Chronic Respiratory DiseaseMay 2, 2025